drugset
drugset / Trial / NCT02898259

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

NCT02898259 ↗

Phase 1/2 Terminated 19 enrolled Brian Hill The Cleveland Clinic · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B cell Lymphoma

Timeline

Start
2017-02-20
Primary completion
2018-10-23
Completion
2022-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixazomib Unknown 2 mg Oral
Subject Ixazomib Unknown 3 mg Oral
Subject Ixazomib Unknown 4 mg Oral
Subject Lenalidomide Other / unclassified 10 mg Oral
Subject Lenalidomide Other / unclassified 20 mg Oral
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

indolent B-cell non-Hodgkin lymphoma